scholarly journals Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity

Circulation ◽  
2000 ◽  
Vol 102 (22) ◽  
pp. 2726-2731 ◽  
Circulation ◽  
2007 ◽  
Vol 116 (2) ◽  
pp. 180-187 ◽  
Author(s):  
Giancarlo Agnelli ◽  
Alexander Gallus ◽  
Samuel Z. Goldhaber ◽  
Sylvia Haas ◽  
Menno V. Huisman ◽  
...  

Author(s):  
P Duroux

Preliminary clinical data showed CY 216 could be effective in the treatment of established DVT. Thus, we undertook an European collaborative controlled randomised study to assess the efficacy and tolerance of this new antithrombotic agent.140 patients presenting a proximal DVT of less than 5 days confirmed by phlebogram, are randomly allocated into 2 groups, one treated by UFH with constant pump infusion, at doses daily adapted to laboratory tests, the other one by CY 216 at a mean daily dosage of 450 aXa IC u** calculated at onset of treatment on body weight, administered daily by 2 sub-cutaneous injections during 10 days, without dosage adaptation whatever the lab. tests results.The efficacy is assessed on comparison on both phlebograms (Harder and Arnessen Indexes) and lung Scans performed before inclusion and after end of treatment. In addition, tolerance is appreciated on the incidence of bleeding complications. Furthermore, incidence of clinical DVT recurrence is assessed at 12th week.The present study is still in progress, 130 patients are included ; the preliminary results tend to show that CY 216 at fixed doses, body weight adapted, is an effective and safe treatment of proximal deep vein thrombosis.* CY 216 : FraxiparineR Choay** Axa IC u : anti-factor Xa Institut Choay unit.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Marit Engeseth ◽  
Tone Enden ◽  
Per Morten Sandset ◽  
Hilde Skuterud Wik

Abstract Background Post-thrombotic syndrome (PTS) is a frequent chronic complication of proximal deep vein thrombosis (DVT) of the lower limb, but predictors of PTS are not well established. We aimed to examine predictors of PTS in patients with long-term PTS following proximal DVT. Methods During 2006–09, 209 patients with a first time acute upper femoral or iliofemoral DVT were randomized to receive either additional catheter-directed thrombolysis or conventional therapy alone. In 2017, the 170 still-living participants were invited to participate in a cross-sectional follow-up study. In the absence of a gold standard diagnostic test, PTS was defined in line with clinical practice by four mandatory, predefined clinical criteria: 1. An objectively verified DVT; 2. Chronic complaints (> 1 month) in the DVT leg; 3. Complaints appeared after the DVT; and 4. An alternative diagnosis was unlikely. Possible predictors of PTS were identified with multivariate logistic regression. Results Eighty-eight patients (52%) were included 8–10 years following the index DVT, and 44 patients (50%) were diagnosed with PTS by the predefined clinical criteria. Younger age and higher baseline Villalta score were found to be independent predictors of PTS, i.e., OR 0.96 (95% CI, 0.93–0.99), and 1.23 (95% CI, 1.02–1.49), respectively. Lack of iliofemoral patency at six months follow-up was significant in the bivariate analysis, but did not prove to be significant after the multivariate adjustments. Conclusions In long-term follow up after high proximal DVT, younger age and higher Villalta score at DVT diagnosis were independent predictors of PTS.


2019 ◽  
Vol 24 (1) ◽  
pp. 80 ◽  
Author(s):  
RaziehSadat Mousavi-Roknabadi ◽  
Afsaneh Dehbozorgi ◽  
Fatemeh Damghani ◽  
Mehrdad Sharifi ◽  
SeyedMahmoudreza Sajjadi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document